多中心前瞻性研究:胶质瘤患者脑脊液与血浆中循环肿瘤DNA检测及其与原发肿瘤的突变一致性
该多中心前瞻性研究纳入37例胶质瘤患者,采用定制八基因NGS面板检测配对脑脊液、血浆和肿瘤样本。32例可分析脑脊液样本中19例(59%)检出ctDNA,肿瘤-脑脊液突变一致性为16/19(84%),血浆ctDNA检出率仅2/14(14%)。作者结论认为脑脊液是胶质瘤ctDNA分析的可靠储库,血浆可检出但阳性率较低。
要点
- 脑脊液ctDNA阳性率为19/32(59%),肿瘤-脑脊液突变一致性为16/19(84%)。
- 血浆ctDNA检出率较低,为2/14(14%),两例均与原发肿瘤一致。
- 脑脊液ctDNA阳性且VAF≥mVAF患者的无进展生存和总生存显著短于VAF低于mVAF者。
核心结论
- 脑脊液是胶质瘤患者ctDNA分析的可靠储库,血浆中可检出ctDNA但阳性率较低,作者提出应开展更大规模前瞻性研究以明确液体活检在该病中的潜在作用。
研究设计与样本
- 西班牙四家三级医院的前瞻性研究,2017年2月至2020年3月共纳入37例胶质瘤患者,采用定制八基因(IDH1、IDH2、ATRX、TP53、PTEN、PIK3CA、EGFR、BRAF)NGS面板检测配对脑脊液、血浆和肿瘤样本。
- 32例患者脑脊液样本可分析,包括新诊断23例和复发9例;WHO第五版分型为IDH突变型星形细胞瘤10例、IDH突变型少突胶质细胞瘤6例、IDH野生型胶质母细胞瘤16例。
主要发现
- 脑脊液ctDNA阳性19/32(59%),阴性13/32(41%);阳性患者中检出1个突变者10/19、2个者7/19、3个者2/19。
- 脑脊液ctDNA突变基因频率为EGFR 8/19(42%)、PTEN 7/19(37%)、TP53 6/19(32%)、IDH1 5/19(26%)、PIK3CA 4/19(21%)。
- 肿瘤-脑脊液突变一致性为16/19(84%)。
- 脑脊液ctDNA阳性且VAF≥mVAF患者的无进展生存和总生存显著短于VAF低于mVAF的ctDNA阳性患者。
- 脑脊液ctDNA与至最近脑脊液储库距离、肿瘤大小或IDH状态无关;血浆ctDNA检出2/14(14%),两例均与原发肿瘤一致。
局限性
- 作者在结论中提出应开展更大规模的前瞻性研究以明确液体活检在该病中的潜在作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cerebrospinal fluid (CSF) stands as an easily accessible reservoir for circulating tumor DNA (ctDNA) analysis in patients with central nervous system (CNS) tumors, although evidence is still limited. Our aim was to prospectively evaluate the feasibility of detecting ctDNA for mutational analysis in CSF and plasma in patients with glioma. METHODS: This was a prospective study of patients with glioma diagnosed at four third-level hospitals in Spain. A customized next-generation sequencing (NGS) eight-gene panel (IDH1, IDH2, ATRX, TP53, PTEN, PIK3CA, EGFR, BRAF) was used in paired CSF, plasma and tumor samples. Mutation concordance occurred when the same pathogenic gene variant was detected in tumor and ctDNA. The prognostic value of ctDNA and that of its median variant allele frequency (mVAF) were analyzed. RESULTS: Between February 2017 and March 2020, 37 patients with glioma were enrolled. The 32 patients with analyzable CSF samples comprised patients with new diagnosis (n = 23) and relapse (n = 9); World Health Organization fifth Edition types: IDH-mutant astrocytoma (n = 10), IDH-mutant oligodendroglioma (n = 6) and IDH-wildtype glioblastoma (n = 16); CSF-ctDNA-positive: 19/32 (59%); and CSF-ctDNA-negative: 13/32 (41%). CSF mutation numbers were 1 (10/19), 2 (7/19) and 3 (2/19). Frequencies of CSF-ctDNA-mutated genes were EGFR (8/19, 42%), PTEN (7/19, 37%), TP53 (6/19, 32%), IDH1 (5/19, 26%) and PIK3CA (4/19, 21%). Tumor-CSF mutation concordance was found in 16/19 (84%). Progression-free and overall survival were significantly shorter in ctDNA-positive patients with VAF equal to or greater than the mVAF compared with ctDNA-positive patients with VAF lower than the mVAF. No association was found between ctDNA in CSF and distance to closest CSF reservoir, tumor size or IDH status. ctDNA was detected in 2 of 14 (14%) individual plasma samples, in both cases concordant with the primary tumor. CONCLUSION: CSF is a reliable reservoir for ctDNA analyses in patients with glioma. ctDNA is detectable in plasma although at a lower rate. Larger, prospective studies should be conducted to refine the potential role of liquid biopsy in this disease.
引用
- Cabezas-Camarero S, Pérez-Alfayate R, García-Barberán V, et al. ctDNA detection in cerebrospinal fluid and plasma and mutational concordance with the primary tumor in a multicenter prospective study of patients with glioma. Ann Oncol. 2025. PMID: 39978637. doi:10.1016/j.annonc.2025.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。